Plain-English translation of NCT05524935 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a type of cancer medication, works better when combined with (an immunotherapy drug) to treat advanced uveal melanoma—a serious cancer of the eye. Researchers believe that combining these two different types of treatment might help the body's immune system fight the cancer more effectively. This study includes about 12 patients and is being led by the Moffitt Cancer Center.
Advanced uveal melanoma is difficult to treat and many patients don't respond well to existing therapies. Doctors believe that combining an immune-boosting medication with this treatment might offer hope to patients who have limited options.
If you join, you will receive an infusion of through an IV every 21 days, and you will take as a pill by mouth twice daily for 21 days, then repeat. This cycle continues for up to 35 cycles (about 2 years) or until the cancer progresses, you experience unacceptable side effects, or you and your doctor decide to stop. You will have regular visits to monitor how you're responding and check for any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Merck Sharp & Dohme LLC
Enrollment target
~12 participants
Started
October 2022
Primary completion
July 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.